QT
DNLI icon

Quantamental Technologies’s Denali Therapeutics DNLI Stock Holding History

Quantamental Technologies’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,307
Closed -$245K – 372
2023
Q2 		$245K Buy
+8,307
New +$234K 0.1% 337
2020
Q4 		– Sell
-6,179
Closed -$221K – 147
2020
Q3 		$221K Buy
+6,179
New +$186K 0.16% 215
2019
Q1 		– Sell
-2,000
Closed -$41K – 1550
2018
Q4 		$41K Buy
+2,000
New +$36.3K 0.02% 833

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Quantamental Technologies's DNLI Position: Q3 2023 in Review

Quantamental Technologies sold out of Denali Therapeutics (DNLI) in Q3 2023, closing a stake of 8,307 shares — an estimated $245K sold.

Quantamental Technologies first reported a position in DNLI in Q4 2018 and held it in 3 quarters. The position peaked at $245K in Q2 2023. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

  • Quantamental Technologies reported no remaining Denali Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Quantamental Technologies sold 8,307 Denali Therapeutics shares in Q3 2023, an estimated $245K.
  • Quantamental Technologies first reported a position in Denali Therapeutics in Q4 2018 and held it in 3 quarters.
  • Quantamental Technologies's Denali Therapeutics position peaked at $245K in Q2 2023.
  • 194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on Quantamental Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.